The current treatment landscape for back of the eye disorders is characterized by the presence of blockbuster novel ophthalmic drugs, such as Lucentis® and Eylea®, and various other therapeutic options. Despite the success of these therapies, their invasive mode of administration, high dosage frequency and other drug related side effects, are some of the drawbacks